Susquehanna Fundamental Investments’s Pacific Biosciences PACB Stock Holding History

Susquehanna Fundamental Investments’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-136,683	Closed	-$161K	–	935
2025 Q1	$161K	Sell	136,683 -56,201	-29%	-$86.2K	﹤0.01%	1011
2024 Q4	$353K	Buy	+192,884	New	+$377K	0.01%	911
2022 Q1	–	Sell	-27,560	Closed	-$564K	–	1653
2021 Q4	$564K	Sell	27,560 -15,599	-36%	-$376K	0.01%	867
2021 Q3	$1.1M	Sell	43,159 -41,220	-49%	-$1.22M	0.02%	818
2021 Q2	$2.95M	Sell	84,379 -31,800	-27%	-$925K	0.05%	467
2021 Q1	$3.87M	Hold	116,179	–	–	0.07%	409
2020 Q4	$3.01M	Buy	116,179 +14,399	+14%	+$245K	0.05%	489
2020 Q3	$1M	Buy	101,780 +16,280	+19%	+$93.7K	0.03%	642
2020 Q2	$295K	Buy	+85,500	New	+$291K	0.01%	745

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna Fundamental Investments's PACB Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of Pacific Biosciences (PACB) in Q2 2025, closing a stake of 136,683 shares — an estimated $161K sold.

Susquehanna Fundamental Investments first reported a position in PACB in Q2 2020 and held it in 9 quarters. The position peaked at $3.87M in Q1 2021. 207 funds tracked by Wall St. Rank hold PACB as of Q2 2025.

Susquehanna Fundamental Investments reported no remaining Pacific Biosciences position as of Q2 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 136,683 Pacific Biosciences shares in Q2 2025, an estimated $161K.
Susquehanna Fundamental Investments first reported a position in Pacific Biosciences in Q2 2020 and held it in 9 quarters.
Susquehanna Fundamental Investments's Pacific Biosciences position peaked at $3.87M in Q1 2021.
207 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.